<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005985</url>
  </required_header>
  <id_info>
    <org_study_id>1996LS155</org_study_id>
    <secondary_id>UMN-MT-9527</secondary_id>
    <secondary_id>UMN-MT-1995-27</secondary_id>
    <nct_id>NCT00005985</nct_id>
  </id_info>
  <brief_title>Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Primed Peripheral Blood Stem Cell Autologous Transplantation for Lymphoma and Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may&#xD;
      allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
      Colony-stimulating factors such as filgrastim may increase the number of immune cells found&#xD;
      in bone marrow or peripheral blood and may help a person's immune system recover from the&#xD;
      side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving filgrastim together with&#xD;
      chemotherapy and peripheral stem cell transplant works in treating patients with Hodgkin's&#xD;
      lymphoma or non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the clinical outcomes, survival, and morbidity of transplantation in patients&#xD;
           with Hodgkin's lymphoma or non-Hodgkin's lymphoma when treated with filgrastim (G-CSF)&#xD;
           followed by high dose chemotherapy plus G-CSF followed by autologous peripheral blood&#xD;
           stem cell (PBSC) transplantation.&#xD;
&#xD;
        -  Determine whether sufficient PBSC can be collected for use in autologous transplantation&#xD;
           in these patients when mobilized with hematopoietic growth factor alone compared to&#xD;
           chemotherapy plus growth factor.&#xD;
&#xD;
        -  Determine whether these primed PBSC support prompt lymphoid and myeloid hematopoietic&#xD;
           recovery after transplantation in these patients.&#xD;
&#xD;
        -  Compare the numbers of committed progenitor cells and/or primitive, pluripotential&#xD;
           hematopoietic stem cells with these two priming techniques.&#xD;
&#xD;
        -  Compare the numbers of tumor cells in cryopreserved PBSC following these priming&#xD;
           techniques.&#xD;
&#xD;
        -  Evaluate response and extended relapse free survival in conjunction with rapid&#xD;
           hematopoietic reconstitution and limited transplant associated morbidity and mortality&#xD;
           in these patients when treated with these regimens.&#xD;
&#xD;
      OUTLINE: In the first priming phase, patients receive filgrastim (G-CSF) subcutaneously (SQ)&#xD;
      daily on days 1-7 and peripheral blood stem cells are collected on days 6-8.&#xD;
&#xD;
      At least 48 hours after the last dose of G-CSF and after the third leukapheresis, patients&#xD;
      receive the second priming, which consists of cyclophosphamide IV over 2 hours on day 1 and&#xD;
      cytarabine IV over 1 hour every 12 hours for a total of 2 doses on day 1. Patients also&#xD;
      receive mitoxantrone IV over 1 hour daily and dexamethasone IV every 12 hours for a total of&#xD;
      4 doses on days 1-2. Patients receive G-CSF SQ daily beginning on day 4 and continuing until&#xD;
      the completion of leukapheresis. PBSC are collected on 3 consecutive days after blood counts&#xD;
      recover.&#xD;
&#xD;
      In the transplant phase, patients with non-Hodgkin's lymphoma who have not exceeded&#xD;
      pretransplant radiotherapy limits receive cyclophosphamide IV over 2 hours on days -7 and -6&#xD;
      and total body irradiation twice daily on days -4 through -1. Autologous PBSC are reinfused&#xD;
      on day 0. Patients receive G-CSF IV daily beginning on day 0 and continuing until day 21 or&#xD;
      until blood counts recover.&#xD;
&#xD;
      Patients with Hodgkin's lymphoma or patients with non-Hodgkin's lymphoma who have exceeded&#xD;
      pretransplant radiotherapy limits receive cyclophosphamide IV over 2 hours daily on days -6&#xD;
      through -3, carmustine IV over 1 hour on day -6, and etoposide IV over 4 hours every 12 hours&#xD;
      for a total of 6 doses on days -6 through -4. Autologous PBSC are reinfused on day 0.&#xD;
      Patients also receive G-CSF IV daily beginning on day 0 and continuing until day 21 or until&#xD;
      blood counts recover.&#xD;
&#xD;
      All patients receive radiotherapy for any residual nodal masses measuring at least 2 cm 5&#xD;
      days a week beginning on day 28.&#xD;
&#xD;
      Patients are followed at day 100, then every 3 months for 1 year, then every 6 months for 2&#xD;
      years, and then annually thereafter.&#xD;
&#xD;
      This was changed to a treatment guideline study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival at 2 years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse or progression transplant related mortality at 1Â½ years</measure>
  </secondary_outcome>
  <enrollment type="Actual">213</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  One of the following histologically confirmed diagnoses&#xD;
&#xD;
               -  High grade non-Hodgkin's lymphoma:&#xD;
&#xD;
                    -  Immunoblastic or small noncleaved cell lymphoma (Burkitt's or non-Burkitt's)&#xD;
                       in complete or partial remission after initial therapy&#xD;
&#xD;
                    -  Localized (stage I or Zeigler stage A) small noncleaved (Burkitt's or&#xD;
                       non-Burkitt's) after relapse or incomplete response to initial therapy&#xD;
&#xD;
                    -  Lymphoblastic lymphoma in second or greater complete or partial response&#xD;
&#xD;
                    -  High risk lymphoblastic lymphoma in first complete remission or after&#xD;
                       initial therapy (high risk factors include stage IV disease, LDH greater&#xD;
                       than 2 times normal, and 2 or more extranodal sites)&#xD;
&#xD;
               -  Intermediate grade non-Hodgkin's lymphoma:&#xD;
&#xD;
                    -  Diffuse large cell lymphoma&#xD;
&#xD;
                    -  Diffuse mixed cell lymphoma&#xD;
&#xD;
                    -  Diffuse small cleaved cell lymphoma&#xD;
&#xD;
                    -  Follicular large cell lymphoma&#xD;
&#xD;
                    -  In second or greater complete or partial remission OR&#xD;
&#xD;
                    -  High risk in first complete remission or after initial therapy&#xD;
&#xD;
                         -  High risk features include:&#xD;
&#xD;
                              -  No complete response after 12 weeks of initial combination&#xD;
                                 chemotherapy&#xD;
&#xD;
                              -  Bulky disease (greater than 10 cm nodal masses or mediastinal&#xD;
                                 disease involving greater than 1/3 of the chest diameter&#xD;
&#xD;
                              -  Malignant pleural effusion&#xD;
&#xD;
                              -  Liver involvement&#xD;
&#xD;
                              -  LDH greater than 2 times upper limit of normal at diagnosis&#xD;
&#xD;
                              -  At least 2 extranodal sites&#xD;
&#xD;
               -  Low grade non-Hodgkin's lymphoma:&#xD;
&#xD;
                    -  Follicular small cleaved cell lymphoma&#xD;
&#xD;
                    -  Follicular mixed cell lymphoma&#xD;
&#xD;
                    -  Diffuse small lymphocytic lymphoma&#xD;
&#xD;
                    -  In first or greater complete response OR&#xD;
&#xD;
                    -  Following initial treatment if complete response is not achieved&#xD;
&#xD;
                    -  In second or greater complete or partial response if treated at diagnosis&#xD;
                       without clinical symptoms necessitating treatment&#xD;
&#xD;
               -  T-cell lymphoma (nonlymphoblastic, intermediate, or high grade lymphomas) after&#xD;
                  initial therapy whether or not complete response is achieved&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
                    -  Stage I and II disease treated with primary radiotherapy and failure of at&#xD;
                       least one combination chemotherapy regimen&#xD;
&#xD;
                    -  Stage III and IV disease with failure on mechlorethamine, vincristine,&#xD;
                       procarbazine, and prednisone (MOPP)-like regimen, alternative noncross&#xD;
                       resistant regimen (e.g., doxorubicin, bleomycin, vinblastine, and&#xD;
                       dacarbazine [ABVD]), or a combination (e.g., MOPP-ABV)&#xD;
&#xD;
                    -  High risk features allowed including:&#xD;
&#xD;
                         -  Failure to achieve initial complete remission with MOPP and/or ABVD and&#xD;
                            crossover or hybrid therapy&#xD;
&#xD;
                         -  Relapse within 6 months after initial therapy&#xD;
&#xD;
                         -  Relapse after initial radiotherapy with complete response longer than 1&#xD;
                            year since initial therapy and subsequent failure on MOPP and/or ABVD&#xD;
                            or hybrid&#xD;
&#xD;
                    -  Bulky mediastinal disease after initial therapy and residual mass of at&#xD;
                       least 5 cm with other features of persisting disease (e.g., Gallium scan&#xD;
                       positive, high LDH, enlarging on serial x-rays, or positive biopsy)&#xD;
&#xD;
          -  No HIV or HTLV-1 associated lymphomas&#xD;
&#xD;
          -  No resistant or refractory lymphoma (no partial response following up to 3 courses of&#xD;
             combination chemotherapy)&#xD;
&#xD;
          -  No active ischemic or degenerative CNS disease NOTE: A new classification scheme for&#xD;
             adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or&#xD;
             &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;, &quot;intermediate&quot;, or&#xD;
             &quot;high&quot; grade lymphoma. However, this protocol uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  70 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Age 65-70 years:&#xD;
&#xD;
               -  Karnofsky 80-100%&#xD;
&#xD;
          -  Under 65 years:&#xD;
&#xD;
               -  ECOG 0-1 (2 allowed if symptoms are directly related to lymphoma)&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No prior or current chronic liver disease&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST and alkaline phosphatase less than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Age 65-70 years:&#xD;
&#xD;
               -  Creatinine clearance greater than 60 mL/min (if creatinine at least 1.5 mg/dL)&#xD;
&#xD;
          -  Under 65 years:&#xD;
&#xD;
               -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
               -  Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 45% by MUGA&#xD;
&#xD;
          -  No symptoms of cardiac disease&#xD;
&#xD;
          -  No active ischemic heart disease&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Age 65-70 years:&#xD;
&#xD;
               -  If history of smoking or respiratory symptoms, spirometry and DLCO must be&#xD;
                  greater than 50% of predicted&#xD;
&#xD;
          -  All ages:&#xD;
&#xD;
               -  No obstructive airway disease&#xD;
&#xD;
               -  No resting hypoxemia (PO_2 less than 80)&#xD;
&#xD;
               -  DLCO at least 50% of predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No poorly controlled diabetes&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Must have prior chemotherapy to attempt to achieve complete response&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No radiotherapy to residual disease prior to transplantation&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Concurrent IV antibiotic therapy allowed for fever or signs of infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J. Weisdorf, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

